Roche wins EU positive opinion for rheumatoid arthritis drug Pharmaceutical Business Review - Nov 25, 2008 By Staff Writer In these patients, RoActemra can be given as monotherapy in cases of intolerance to methotrexate (MTX) or where continued treatment with MTX ...
Leucovorin injection shortage Prescribing Reference, New York - Nov 20, 2008 ... advanced colorectal cancer in combination with 5-fluorouracil, rescue treatment after high-dose methotrexate therapy in osteosarcoma and the treatment ...
US FDA Grants Pralatrexate Orphan Drug Designation for the ... MarketWatch - Nov 24, 2008 The Company believes PDX has the potential to be delivered as a single agent or in combination therapy regimens. Allos Therapeutics is a biopharmaceutical ...
Source: Google News
Recent News and Articles on the Keywords: 0.37 + web + 9,250 Related to the article below (Last Update: 8/7/2008)
AtriCure Reports Record Second Quarter 2008 Financial Results PR Newswire (press release), NY - Aug 5, 2008 A live web cast of the conference call will be available online from the investor relations page of AtriCure's corporate web site at http://www.atricure.com ...ATRC
Cuil The Conquerer: No Way! EFYTimes (press release), India - Jul 28, 2008 (0.37 seconds) . This gives an idea of how much comprehensive the search is as of now. Now coming to the content, when we searched for EFYTimes, ...
Caribou Coffee Reports Second Quarter 2008 Results Trading Markets (press release), CA - Aug 5, 2008 For more information, visit the Caribou Coffee web site at www.cariboucoffee.com . Certain statements in this release, and other written or oral statements ...CBOU
Littelfuse Reports Second Quarter Results MarketWatch - Jul 30, 2008 The call will be broadcast live over the Internet and can be accessed through the company's Web site: www.littelfuse.com. Listeners should go to the Web...LFUS
Source: Google News
[CITATION] Subsidiary Debt and the Efficiency of Conglomerate Capital Allocation AC Kolasinski -
[PDF]ESO Imaging Survey - S Arnouts, B Vandame, C Benoist, MAT Groenewegen, … - Arxiv preprint astro-ph/0103071, 2001 - arxiv.org ... eis proj/public/wfi chip.html? as well as at other locations on the ESO web pages ...
arcsec) U 47600 55 0.98 U ??? 43600 49 1.06 B a 24500 30 1.02 V 9250 33 0.97 ... -
Parent Stars of Extrasolar Planets. VI. Abundance Analyses of 20 New Systems - G Gonzalez, C Laws, S Tyagi, BE Reddy - The Astronomical Journal, 2001 - UChicago Press ... remaining sample, we derive [Fe/H] estimates ranging from -0.41 to +0.37, with
an ... the McDonald 2.7 m). We also added a new synthesized region: 9250?9270 ? ...
Turing instability mediated by voltage and calcium diffusion in paced cardiac cells - Y Shiferaw, A Karma - Proceedings of the National Academy of Sciences, 2006 - National Acad Sciences ... The pacing rate is 0.35 s, with T c = 0.37 s. (B) Strong Ca-induced ... given in Tables
1?7, which are published as supporting information on the PNAS web site. ...
[PDF]LOW TEMPERATURE, SPOT CURE CONDUCTIVE ADHESIVE TECHNOLOGIES FOR RFID TAGS ASSEMBLY - J Shah, B Xia, S Cheng, WO'Hara, V Buffa - Change - emersoncuming.com ... technology, which translates in > 150 ft/min web speed . ...0.37 0.39 0.38 0.37 0.33
0.35 0.35 0.35 ... performance of the RFID Tags, Alien ALL-9250 ?I2? antennas ...
[PDF]After Transfer of Sludge from BVEST, GAAT, and OHF Tanks - JM Keller, JM Giaquinto - ORNL - osti.gov ...Web site http://www.osti.gov/bridge Reports produced before January 1, 1996, may
be purchased by members of the public from the following source. ...
Source: Google Scholar
Combination therapy, Adalimumab plus Methotrexate, for achieving remission of early rheumatoid arthritis
Two-year study of patients with early, aggressive disease demonstrates significantly superior results of anti-TNF plus DMARD therapy over either therapy alone.
A chronic and potentially crippling inflammatory disorder, rheumatoid arthritis progressively wears away the cartilage and bone. Joint erosions are routinely seen within 6 months of rheumatoid arthritis 's onset, and occur more rapidly earlier in the course of the disease. Moderate disability within 2 years of diagnosis is not uncommon.
While conventional DMARD ( disease-modifying antirheumatic drug ) therapies have been shown to slow joint destruction, they are powerless to stop rheumatoid arthritis' progression or reverse joint damage.
As researchers widely agree, early intervention offers rheumatoid arthritis patients the most promise for preventing irreversible joint damage and avoiding severe disability.
In addition to early treatment, combination treatment, with DMARDs as well as with biologic agents, has been shown to yield more favorable outcomes than a single treatment.
The study has compared the effectiveness of DMARD therapy alone, anti-TNF ( tumor necrosis factor ) therapy alone, and a combination of DMARD and anti-TNF therapy. The compelling results affirm the long-term benefits of early combination therapy for women and men afflicted with aggressive rheumatoid arthritis.
The study was conducted at 133 sites throughout North America, Europe, and Australia. It focused on patients with active rheumatoid arthritis for less than 3 years who had never been treated with the DMARD Methotrexate ( MTX ).
A total of 799 patients were enrolled in the study. The majority were women. The mean age was 52 years. 57 percent of the participants had rheumatoid arthritis for 6 months or less.
The subjects were randomly divided into one of 3 treatment groups: Methotrexate, in pill form, starting with 20 milligrams weekly; the anti-TNF Adalimumab ( Humira ), administered by injection, starting with 40 milligrams every other week; and a combination of Adalimumab plus Methotrexate, starting at the same dosage levels as the single treatment groups.
For all groups, treatment effectiveness was thoroughly evaluated after 6 months, 1 year, and 2 years. 539 of the participants completed 2 years of their assigned treatment.
In all outcome measured, the combination of treatments was clinically and statistically superior to both Adalimumab and Methotrexate alone.
Following 1 year of treatment, 62 percent of patients in the combination therapy group had 50 percent improvement in disease symptoms, according to the standard American College of Rheumatology ( ACR ) criteria, compared with 41 percent of patients in the Adalimumab only group and 46 percent of patients in the Methotrexate only group.
In addition, there was significantly less radiographic disease progression at 6 months, 1 year, and 2 years among patients in the combination treatment group than among those in either single treatment group.
After 2 years of treatment, nearly half the patients in the combination therapy group exhibited a major clinical remission, rates approximately twice those found among patients receiving either single therapy.
The combination of DMARD and anti-TNF therapy proved safe and well tolerated by patients. The incidence of infections and other adverse events were low and comparable in all 3 treatment groups. Increasing the dosages of either Adalimumab or Methotrexate alone failed to yield the improvements experienced by patients receiving both treatments in relatively low dosages.
Early rheumatoid arthritis patients with milder forms of the disease may benefit from early DMARD therapy under a clinician's supervision. "For the patient with early, aggressive and erosive, RA," he notes, "treatment with combination therapy is superior to treatment with Methotrexate alone."
